Vanda Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNDA research report →
Range $10 – $10
Price Chart
About the company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia.
- CEO
- Mihael H. Polymeropoulos
- IPO
- 2006
- Employees
- 533
- HQ
- Washington, DC, US
Get TickerSpark's AI analysis on VNDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $208.32M
- P/E
- -0.75
- Fwd P/E
- 22.47
- PEG
- 0.00
- P/S
- 0.91
- P/B
- 1.04
- EV/EBITDA
- -1.04
- Div Yield
- 0.00%
- Gross Margin
- 92.72%
- Op Margin
- -77.59%
- Net Margin
- -119.87%
- ROE
- -106.94%
- ROIC
- -76.68%
Latest fiscal year · YoY change
- Revenue
- $216.10M+8.7%
- Gross Profit
- $203.06M+8.3%
- Op Income
- $-151,168,000
- Net Income
- $-220,474,000-1066.5%
- EPS
- $-3.74-1068.8%
- OCF Growth
- -594.6%
- FCF Growth
- -579.8%
- 52W High
- $9.94
- 52W Low
- $3.42
- 50D MA
- $4.38
- 200D MA
- $5.94
- Beta
- 0.73
- RSI (14)
- 32
- Avg Volume
- 1.05M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vanda reported a strong Q3 with revenue up 24% year over year, driven by Fanapt and a growing NEREUS launch, while management guided to further expense declines and more product catalysts ahead.· October 28, 2026
- Q3 revenue rose to $69.8 million, up 24% from $56.3 million a year ago, with net loss unchanged at $22.6 million year over year and down from $62.5 million in Q2.
- Fanapt continued to lead growth: Q3 sales were $38.8 million, up 24% year over year, and prescriptions rose 25% with weekly TRx reaching an 11-year high in September.
- HETLIOZ sales jumped to $21.7 million in Q3, but management warned future revenue could be volatile and potentially decline due to specialty pharmacy stocking changes and generic competition.
- NEREUS is still early but gaining traction: Q3 sales were $1.6 million, refills are starting, and management said both total prescriptions and unique prescribers were up over 100% sequentially.
- Operating expenses fell to $93.3 million in Q3 from $114.3 million in Q2, and management expects further declines as phase III and launch-related work winds down.
Total revenues were $69.8 million in Q3 2026, up 24% from $56.3 million in Q3 2025 and up 38% from $50.5 million in Q2 2026. Q3 net loss was $22.6 million, flat versus $22.6 million a year ago and improved from a $62.5 million loss in Q2 2026. Operating expenses were $93.3 million, up from $87.5 million a year ago but down from $114.3 million in Q2 2026. Product sales in Q3 were Fanapt $38.8 million (+24% y/y), HETLIOZ $21.7 million (+21% y/y), PONVORY $7.7 million (+10% y/y), and NEREUS $1.6 million (+60% q/q). Cash equivalents and marketable securities were $140.5 million at September 30, 2026. For full-year 2026, management now expects total revenues from Fanapt, BYSANTI, HETLIOZ, PONVORY, and NEREUS of greater than $240 million. Management said NEREUS full-year 2026 revenue will likely be less than $10 million, and it is not providing 2026 cash guidance, though cash burn is likely to be greater than in 2025.
The CEO emphasized that Vanda is shifting from a period of heavy clinical and launch investment toward a phase of lower costs and more visible commercial execution. He highlighted strong Fanapt momentum, the upcoming BYSANTI launch, positive phase III data for NEREUS in GLP-1-induced vomiting, and positive HETLIOZ data in delayed sleep-wake phase disorder as major catalysts. His tone was confident and upbeat, but tempered by acknowledgment that several programs still require FDA interactions and timing remains uncertain.
The CFO focused on the quarter’s financial improvement and the expected operating leverage from lower development and launch spending. He noted Q3 revenue of $69.8 million, Q3 operating expenses of $93.3 million, and Q3 net loss of $22.6 million, versus $114.3 million of operating expenses in Q2 and a $62.5 million net loss in Q2. He also said cash was $140.5 million at quarter-end, down $123.4 million from year-end 2025, in part because of a $10 million milestone payment to Eli Lilly in Q1 2026. He reiterated that cash burn in 2026 is likely higher than in 2025, but operating expenses should decline further in future quarters as remaining phase III and launch activities conclude.
Analysts focused on Quimilza launch timing, the BYSANTI MDD program, the iloperidone LAI program, and how the GLP-1 vomiting data supports labeling and review priority. Management said Quimilza could be ready a few months after the December 12 PDUFA, with a goal of launching in the first half of 2027, and that BYSANTI MDD is more than 50% enrolled with completion targeted in the first half of 2027. On iloperidone LAI, management said slow recruitment and unexpectedly low relapse rates are prompting consideration of a PK bridging proposal instead of the current path. For the GLP-1 program, management said the primary endpoint will support the sNDA, supplemented by phase II, pooled, and key secondary analyses; it also described the treatment as short-course, preventive use around initiation or titration rather than chronic use.
The call showed multiple near-term catalysts: BYSANTI launch expected in Q4 2026, Quimilza FDA action on December 12, and additional regulatory steps for NEREUS and HETLIOZ. Commercially, Fanapt is still accelerating, with prescriptions up 25% and management describing strong prescriber receptivity. Management also signaled that operating expenses should keep falling, which could improve the earnings profile if revenue growth continues.
HETLIOZ remains exposed to generic competition, and management explicitly warned that sales may decline significantly in future periods depending on specialty pharmacy stocking and demand patterns. NEREUS is still very early, with management saying 2026 revenue will likely be less than $10 million and that uptake may be slower as awareness builds. Cash burn is expected to be higher in 2026 than 2025, and several key programs still depend on FDA decisions, approvals, or further clinical/regulatory work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.6%
- Shares Outstanding
- 60.47M
- Float Shares
- 57.21M
of shares held by institutions
177 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.47M | ▲ 812.45K |
| Vanguard Group Inc | 3.73M | ▲ 144.71K |
| Aqr Capital Management LLC | 3.50M | ▲ 1.89M |
| Renaissance Technologies LLC | 3.31M | ▼ 132.92K |
| State Street Corp | 3.01M | ▼ 505.87K |
| Vanguard Capital Management LLC | 2.54M | ▲ 13.59K |
| Aigh Capital Management LLC | 2.25M | ▲ 205.83K |
| Marshall Wace, Llp | 2.08M | ▲ 856.84K |
| Acadian Asset Management LLC | 1.78M | ▼ 138.31K |
| Dimensional Fund Advisors LP | 1.75M | ▲ 21.57K |
| Millennium Management LLC | 1.60M | ▼ 278.19K |
| Federated Hermes, Inc. | 1.60M | ▲ 885.36K |
Held by 210 ETFs
Biggest fund positions in VNDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | Duncan Charles Cliff | buy | 5,803 |
| Nov 4, 26 | Duncan Charles Cliff | buy | 3,447 |
| Nov 3, 26 | Duncan Charles Cliff | buy | 750 |
| Jun 4, 26 | McGuire Daniel Patrick | other | 80,000 |
| Jun 4, 26 | Chrousos Phaedra | other | 41,600 |
| Jun 4, 26 | Duncan Charles Cliff | other | 41,600 |
| Jun 4, 26 | DUGAN RICHARD W | other | 41,600 |
| Jun 4, 26 | Ward Anne Sempowski | other | 41,600 |
| Jun 4, 26 | Honore Tage | other | 41,600 |
| Jun 4, 26 | Mitchell Stephen Ray | other | 41,600 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VNDA coverage
Recent articles, reports, and earnings notes.
No research on VNDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VNDA report →Financial Review: Vanda Pharmaceuticals (NASDAQ:VNDA) vs. Siga Technologies (NASDAQ:SIGA)
defenseworld.net · Nov 14
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
prnewswire.com · Nov 11
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
prnewswire.com · Nov 3
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Vanda Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Oct 28
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 28
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
prnewswire.com · Oct 28
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
benzinga.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.